News & Updates

Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.

The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.

Research from the University of Hong Kong (HKU) demonstrates that intranasal influenza-based booster vaccination following PD1-based receptor-binding domain (RBD) DNA vaccine induces mucosal and systemic immunity for effective prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both upper and lower respiratory systems of mice.

A self-controlled case series reported by researchers from the University of Hong Kong has identified an increased risk of herpes zoster–related hospitalization associated with mRNA-based BNT162b2 and inactivated CZ02 vaccination against coronavirus disease 2019 (COVID-19).

A study by the University of Hong Kong (HKU) has found that immune sera from mRNA-based BNT162b2 and inactivated CZ02 vaccine recipients have substantially reduced neutralizing antibody titres against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.

An online survey of over 2,500 Hong Kong adolescents has identified knowing someone diagnosed with coronavirus disease 2019 (COVID-19), having at least one vaccinated parent, and receiving the influenza vaccine in the past year as three top predictors of COVID-19 vaccine acceptance.

Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.